Literature DB >> 24090502

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.

Magdalena Koszarska1, Nora Meggyesi, Andras Bors, Arpad Batai, Otto Csacsovszki, Eniko Lehoczky, Emma Adam, Andras Kozma, Nora Lovas, Andrea Sipos, Tunde Krahling, Janos Dolgos, Peter Remenyi, Sandor Fekete, Tamas Masszi, Attila Tordai, Hajnalka Andrikovics.   

Abstract

Internal tandem duplications (ITDs) of the fms-like tyrosine kinase 3 (FLT3) gene occur in about 25% of patients with adult acute myeloid leukemia (AML). The aim of our study was to investigate the frequency of FLT3-ITD mutations followed by a detailed analysis of the mutational load and size of ITD insertions in a cohort consisting of 324 patients younger than 60 years old and treated with curative intention. FLT3-ITD alone did not influence overall survival (OS) or disease-free survival (DFS). We observed worse OS and DFS for patients with high mutational load indicative for loss of the FLT3 wild type allele (p = 0.010, p = 0.038, respectively). In multivariate analyses, patients with FLT3-ITD(48-60bp) showed worse OS and DFS compared to other groups (FLT3-ITD(neg), FLT3-ITD (< 48b), FLT3-ITD (> 60bp); p = 0.014, p = 0.019, respectively). Our novel observation suggested that not only high FLT3-ITD load, but also medium-sized ITD insertions (48-60 bp) represented an adverse prognostic subgroup of patients with AML.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3 internal tandem duplication; molecular genetics; mutation

Mesh:

Substances:

Year:  2013        PMID: 24090502     DOI: 10.3109/10428194.2013.850163

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study.

Authors:  Elizabeth M Corley; Moaath K Mustafa Ali; Hanan Alharthy; Kathryn A F Kline; Danielle Sewell; Jennie Y Law; Seung Tae Lee; Sandrine Niyongere; Vu H Duong; Maria R Baer; Ashkan Emadi
Journal:  Biology (Basel)       Date:  2022-06-15

2.  Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Authors:  Akira Shimada; Yuka Iijima-Yamashita; Akio Tawa; Daisuke Tomizawa; Miho Yamada; Shiba Norio; Tomoyuki Watanabe; Takashi Taga; Shotaro Iwamoto; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Katsuyoshi Koh; Hiroaki Goto; Yoshiyuki Kosaka; Akiko Moriya Saito; Nobutaka Kiyokawa; Keizo Horibe; Yusuke Hara; Kentaro Oki; Yasuhide Hayashi; Shiro Tanaka; Souichi Adachi
Journal:  Int J Hematol       Date:  2018-01-12       Impact factor: 2.490

3.  Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.

Authors:  Fang Chen; Junya Sun; Changxin Yin; Jiaying Cheng; Jinle Ni; Ling Jiang; Qiang Wang; Guopan Yu; Yongqiang Wei; Xiaoli Liu; Jing Sun; Bing Z Carter; Xuejie Jiang
Journal:  Bone Marrow Transplant       Date:  2019-10-23       Impact factor: 5.483

4.  FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.

Authors:  Vanessa Y N de Arruda; Lisa N Matsuzaki; Maria de Lourdes Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2017-04-03

Review 5.  "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.

Authors:  Tristan E Knight; Holly Edwards; Soheil Meshinchi; Jeffrey W Taub; Yubin Ge
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

6.  Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios.

Authors:  Kun-Yin Qiu; Xiong-Yu Liao; Yong Liu; Ke Huang; Yang Li; Jian-Pei Fang; Dun-Hua Zhou
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

Review 7.  Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

Authors:  Caroline Benedicte Nitter Engen; Line Wergeland; Jørn Skavland; Bjørn Tore Gjertsen
Journal:  J Clin Med       Date:  2014-12-15       Impact factor: 4.241

Review 8.  Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.

Authors:  Kenichi Miyamoto; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

9.  FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.

Authors:  Caroline Engen; Monica Hellesøy; Tim Grob; Adil Al Hinai; Atle Brendehaug; Line Wergeland; Siv Lise Bedringaas; Randi Hovland; Peter J M Valk; Bjørn T Gjertsen
Journal:  Mol Oncol       Date:  2021-05-02       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.